caa a22 4500 469121211 CHVBK 20180323133139.0 cr unu---uuuuu 170328e19920301xx s 000 0 eng 10.1007/BF02245421 doi (NATIONALLICENCE)springer-10.1007/BF02245421 Memory modulation with peripherally acting cholinergic drugs [Elektronische Daten] [Douglas Rush, Kornelia Streit] Physostigmine (PHYSO), in doses as low as 0.003 mg/kg IP, antagonized scopolamine (SCOP, 3 mg/kg) induced amnesia of step-through passive avoidance in mice. The peripherally acting acetylcholinesterase (AChE) inhibitor neostigmine (NEO) was also found to reliably, though less strongly, antagonize the SCOP induced amnesia at a dose of 0.03 mg/kg. The NEO antagonism of the SCOP amnesia could be reversed with SCOP (0.3, 1, and 3 mg/kg) and mecamylamine (MECA, 1, 3, and 10 mg/kg), muscarinic and nicotinic antagonists, respectively, which are active both peripherally and centrally, as well as with M-SCOP (0.3 and 1 mg/kg) and hexamethonium (HEX, 1 and 3 mg/kg), muscarinic and nicotinic antagonists, respectively, which are active only in the periphery. In contrast to the ability of these four compounds to attenuate the SCOP amnesia, only the centrally acting compounds SCOP (3 mg/kg) and MECA (10 mg/kg) induced an amnesia when administered alone. These findings suggest that the induction of amnesia of passive avoidance involves central cholinergic systems, whereas the NEO, and possibly PHYSO, reversal of the SCOP induced amnesia is mediated peripherally by both muscarinic and nicotinic receptors. It is hypothesized that the release of adrenal catecholamines, the influence of which on memory processes is well known, and secondarily glucose, may be responsible for the NEO antagonism of the SCOP amnesia. Springer-Verlag, 1992 Mice nationallicence Passive avoidance/Memory nationallicence Amnesia nationallicence Scopolamine nationallicence Methyl scopolamine nationallicence Physostigmine nationallicence Neostigmine nationallicence Mecamylamine nationallicence Hexamethonium nationallicence Rush Douglas Cassella AG, Department of CNS Pharmacology, W-6000, Frankfurt, Federal Republic of Germany aut Streit Kornelia Cassella AG, Department of CNS Pharmacology, W-6000, Frankfurt, Federal Republic of Germany aut Psychopharmacology Springer-Verlag 106/3(1992-03-01), 375-382 0033-3158 106:3<375 1992 106 213 https://doi.org/10.1007/BF02245421 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/BF02245421 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Rush Douglas Cassella AG, Department of CNS Pharmacology, W-6000, Frankfurt, Federal Republic of Germany aut NATIONALLICENCE 700 1- Streit Kornelia Cassella AG, Department of CNS Pharmacology, W-6000, Frankfurt, Federal Republic of Germany aut NATIONALLICENCE 773 0- Psychopharmacology Springer-Verlag 106/3(1992-03-01), 375-382 0033-3158 106:3<375 1992 106 213 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer